Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11521013 | 0.84 | SMYD3 (0.42) | SRCCYP19A1 | |
| SCHEMBL30457762 | 0.83 | NR1H4 (0.46) | GAACTSLCTSSCTSKCTSB | |
| SCHEMBL3707313 | 0.78 | KMT2A (0.46) | SRCALDH1A1MAPK1MAPK14 | |
| SCHEMBL15495599 | 0.72 | HTT (0.39) | HTTGAACYP4F2CYP4A11EPHX2 | |
| SCHEMBL4134269 | 0.72 | DPP4 (0.43) | HTTGAAEPHX2SRCALDH1A1 | |
| SCHEMBL17039107 | 0.72 | HTT (0.39) | HTTGAACYP4F2CYP4A11EPHX2 | |
| SCHEMBL908481 | 0.72 | LMNA (0.43) | HTTGAAEPHX2SRCALDH1A1 | |
| Hydrochloric Acid SCHEMBL1375015 | 0.70 | LMNA (0.42) | HTTGAAEPHX2SRCALDH1A1 | |
| SCHEMBL28759020 | 0.70 | CYP4F2 (0.43) | HTTGAACYP4F2CYP4A11SRC | |
| SCHEMBL3730288 | 0.70 | NOTUM (0.49) | HTTCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-0918758-B1 | PROCESS FOR PREPARING 1-SUBSTITUTED 4-CYANO-1,2,3-TRIAZOLES | NOVARTIS AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| US-6156907-A | Process for preparing 1-substituted 4-cyano-1,2,3-triazoles | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | GLS, ATP6V1B1, PFKP | STAT3 2324/4885HTT 4163/4885GAA 1923/4885 |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | STAT3 2324/4885HTT 4163/4885GAA 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.